Cutler Group’s Aerie Pharmaceuticals AERI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-39,700
| Closed | -$8K | – | 6366 |
|
|
2021
Q4 | $8K | Buy |
+39,700
| New | +$415K | ﹤0.01% | 3916 |
|
|
2020
Q1 | – | Sell |
-12,900
| Closed | -$59K | – | 4884 |
|
|
2019
Q4 | $59K | Sell |
12,900
-3,400
| -21% | -$70.4K | ﹤0.01% | 1520 |
|
|
2019
Q3 | $41K | Buy |
16,300
+14,300
| +715% | +$328K | ﹤0.01% | 1697 |
|
|
2019
Q2 | $22K | Sell |
2,000
-1,600
| -44% | -$61.6K | ﹤0.01% | 2146 |
|
|
2019
Q1 | $18K | Sell |
3,600
-6,400
| -64% | -$282K | ﹤0.01% | 2128 |
|
|
2018
Q4 | $11K | Buy |
10,000
+6,100
| +156% | +$286K | ﹤0.01% | 2499 |
|
|
2018
Q3 | $11K | Buy |
3,900
+100
| +3% | +$6.43K | ﹤0.01% | 2621 |
|
|
2018
Q2 | $31K | Sell |
3,800
-500
| -12% | -$28K | ﹤0.01% | 1919 |
|
|
2018
Q1 | $13K | Sell |
4,300
-12,400
| -74% | -$694K | ﹤0.01% | 2612 |
|
|
2017
Q4 | $41K | Sell |
16,700
-14,900
| -47% | -$904K | ﹤0.01% | 2028 |
|
|
2017
Q3 | $75K | Buy |
31,600
+2,600
| +9% | +$142K | ﹤0.01% | 1901 |
|
|
2017
Q2 | $192K | Buy |
29,000
+4,100
| +16% | +$191K | 0.01% | 1321 |
|
|
2017
Q1 | $68K | Sell |
24,900
-36,800
| -60% | -$1.64M | ﹤0.01% | 2097 |
|
|
2016
Q4 | $189K | Sell |
61,700
-122,400
| -66% | -$4.63M | 0.01% | 1336 |
|
|
2016
Q3 | $1.02M | Buy |
184,100
+178,000
| +2,918% | +$3.93M | 0.05% | 320 |
|
|
2016
Q2 | $20K | Buy |
+6,100
| New | +$98.7K | ﹤0.01% | 3388 |
|
|
2016
Q1 | – | Sell |
-25,300
| Closed | -$62K | – | 7421 |
|
|
2015
Q4 | $62K | Buy |
+25,300
| New | +$590K | ﹤0.01% | 2238 |
|
Cutler Group's AERI Position: Q4 2022 in Review
Cutler Group sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 2,000 shares — an estimated $30K sold.
Cutler Group first reported a position in AERI in Q4 2015 and held it in 23 quarters. The position peaked at $903K in Q3 2016. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.
- Cutler Group reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
- Cutler Group sold 2,000 Aerie Pharmaceuticals shares in Q4 2022, an estimated $30K.
- Cutler Group first reported a position in Aerie Pharmaceuticals in Q4 2015 and held it in 23 quarters.
- Cutler Group's Aerie Pharmaceuticals position peaked at $903K in Q3 2016.
- 0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.
Based on Cutler Group's 13F filing for Q4 2022, filed 7 Feb 2023.